our mission:
to make life
worth living again
for millions of patients.
our mission:
to make life
worth living again
for millions of patients.
company profile
We are a multi-asset, CNS-first clinical stage pharmaceutical company that grew out of an R&D team at a Big Pharma company. We are dedicated to developing novel drugs and technologies for patients suffering from neurological and psychiatric conditions.
We have a rich and growing pipeline and are currently focused on the development of safe and effective treatments to address patients’ unmet needs in Major Depressive Disorder, Parkinson’s Disease, Chronic Pain, and other conditions involving impairment of the neurological system. Our lead drug candidate is currently in a Phase 2 multicenter study in the United States.
One of our driving principles is to invent new therapeutic modalities and bring them quickly from an idea to Proof of Concept and then to full clinical development. Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for patients.
quick facts
Pipeline
5 drugs under development
Types of drugs
small molecules, drugs and
drug-device combinations
Indications
depression, pain and
other CNS indications
Driven by Innovation
Technological and therapeutic ingenuity
translates to new solutions for patients
Passionate Team
With years of experience in Pharma,
Drug Delivery, Medical Practice and
Regulatory Agencies
Solid Foundation
Started in 2018 as a spin-off from a
Big Pharma company, with strong financial
backing and a broad network of
partners worldwide
We believe in the power of collaboration – both internally and externally.
Our team and partners are the key ingredients in our success.